Current and historical daily PE Ratio for GANX (
Gain Therapeutics Inc
) from 2021 to Jun 19 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Gain Therapeutics stock (GANX) PE ratio as of Jun 19 2024 is 0.
More Details
Gain Therapeutics Inc (GANX) PE Ratio (TTM) Chart
Gain Therapeutics Inc (GANX) PE Ratio (TTM) Historical Data
View and export this data going back to 2021. Start your Free Trial
Total 825
- 1
- 2
- 3
- 4
- 5
- 6
- 10
Gain Therapeutics PE Ratio (TTM) Historical Data | |||
---|---|---|---|
Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
2024-06-19 | At Loss | 2024-04-17 | At Loss |
2024-06-18 | At Loss | 2024-04-16 | At Loss |
2024-06-17 | At Loss | 2024-04-15 | At Loss |
2024-06-14 | At Loss | 2024-04-12 | At Loss |
2024-06-13 | At Loss | 2024-04-11 | At Loss |
2024-06-12 | At Loss | 2024-04-10 | At Loss |
2024-06-11 | At Loss | 2024-04-09 | At Loss |
2024-06-10 | At Loss | 2024-04-08 | At Loss |
2024-06-07 | At Loss | 2024-04-05 | At Loss |
2024-06-06 | At Loss | 2024-04-04 | At Loss |
2024-06-05 | At Loss | 2024-04-03 | At Loss |
2024-06-04 | At Loss | 2024-04-02 | At Loss |
2024-06-03 | At Loss | 2024-04-01 | At Loss |
2024-05-31 | At Loss | 2024-03-29 | At Loss |
2024-05-30 | At Loss | 2024-03-28 | At Loss |
2024-05-29 | At Loss | 2024-03-27 | At Loss |
2024-05-28 | At Loss | 2024-03-26 | At Loss |
2024-05-27 | At Loss | 2024-03-25 | At Loss |
2024-05-24 | At Loss | 2024-03-22 | At Loss |
2024-05-23 | At Loss | 2024-03-21 | At Loss |
2024-05-22 | At Loss | 2024-03-20 | At Loss |
2024-05-21 | At Loss | 2024-03-19 | At Loss |
2024-05-20 | At Loss | 2024-03-18 | At Loss |
2024-05-17 | At Loss | 2024-03-15 | At Loss |
2024-05-16 | At Loss | 2024-03-14 | At Loss |
2024-05-15 | At Loss | 2024-03-13 | At Loss |
2024-05-14 | At Loss | 2024-03-12 | At Loss |
2024-05-13 | At Loss | 2024-03-11 | At Loss |
2024-05-10 | At Loss | 2024-03-08 | At Loss |
2024-05-09 | At Loss | 2024-03-07 | At Loss |
2024-05-08 | At Loss | 2024-03-06 | At Loss |
2024-05-07 | At Loss | 2024-03-05 | At Loss |
2024-05-06 | At Loss | 2024-03-04 | At Loss |
2024-05-03 | At Loss | 2024-03-01 | At Loss |
2024-05-02 | At Loss | 2024-02-29 | At Loss |
2024-05-01 | At Loss | 2024-02-28 | At Loss |
2024-04-30 | At Loss | 2024-02-27 | At Loss |
2024-04-29 | At Loss | 2024-02-26 | At Loss |
2024-04-26 | At Loss | 2024-02-23 | At Loss |
2024-04-25 | At Loss | 2024-02-22 | At Loss |
2024-04-24 | At Loss | 2024-02-21 | At Loss |
2024-04-23 | At Loss | 2024-02-20 | At Loss |
2024-04-22 | At Loss | 2024-02-19 | At Loss |
2024-04-19 | At Loss | 2024-02-16 | At Loss |
2024-04-18 | At Loss | 2024-02-15 | At Loss |
Gain Therapeutics Inc (GANX) PE Ratio (TTM) Comparison
Company | Market Cap(Mil) | PE Ratio (TTM) |
---|
Business Description
Business Description
Gain Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US36269B1052
Description
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.